Fiche publication
Date publication
novembre 2019
Journal
Journal of proteome research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NAMER Izzie-Jacques
,
Dr BENDER Laura
,
Dr SOMME François
,
Dr BUND Caroline
Tous les auteurs :
Bender L, Somme F, Ruhland E, Cicek E, Bund C, Namer IJ
Lien Pubmed
Résumé
Background Meningiomas are in most cases benign brain tumors. The WHO 2016 classification defines three grades of meningioma. This classification had a prognosis value since grade III meningiomas have a worse prognosis value compared to grades I and II. However, some benign or atypical meningiomas can have clinical aggressive behavior. There are currently no reliable markers which allow distinguishing between the meningiomas with a good prognosis and those which may recur. Results We retrospectively analyzed 62 meningioma samples by using high-resolution magic angle spinning (HRMAS) spectrometry (43 metabolites). We described a metabolic profile defined by a high concentration for acetate, threonine, N-acetyl-lysine, hydroxybutyrate, myoinositol, ascorbate, scylloinositol, total choline and a low concentration for aspartate, glucose, isoleucine, valine, adenosine, arginine and alanine. This metabolomics signature was associated with poor prognosis histological markers (Ki-67 ≥ 40%, high histological grade, and negative progesterone receptor expression). We also described a similar metabolomics spectrum between grade III and grade I meningioma. Moreover, all grade I meningioma with low Ki-67 expression and positive progesterone receptor expression did not have the same metabolomics profile. Conclusions The metabolomics analysis could be used to determine an aggressive meningioma in order to discuss a personalized treatment. Further studies are needed to confirm these results and to correlate this metabolic profile with survival data.
Référence
J. Proteome Res.. 2019 Nov 4;:
